Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set...

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Multiple myeloma risk stratification traditionally uses 3'-end gene expression profiling (GEP) microarrays.
• This study investigates the prognostic utility of GEP risk signatures when applied to whole-transcript microarray data.

Purpose of the Study:

• To determine if translated GEP risk signatures maintain prognostic power in multiple myeloma patients undergoing high-dose therapy (HDT).
• To evaluate the effectiveness of probe set matching for translating GEP signatures to different microarray platforms.

Main Methods:

• Analysis of CD138-positive bone marrow plasma cells from 59 newly diagnosed and 67 relapsed HDT multiple myeloma patients.
• Application of nine translated GEP risk signatures using Affymetrix Human Gene 1.1 ST microarrays.
• Multivariate Cox regression analysis incorporating clinical, cytogenetic, and biochemical risk markers, including the International Staging System (ISS).

Main Results:

• Translated GEP risk signatures showed significant correlation with progression-free and overall survival.
• Prognostic power was enhanced when combined with cytogenetic markers in newly diagnosed patients and ISS stage III in relapsed patients.
• Median follow-up was 66 months.

Conclusions:

• Translated GEP risk signatures are valuable prognostic tools for HDT multiple myeloma patients.
• Probe set matching is a viable method for translating GEP risk signatures, supporting the development of a standardized, platform-independent approach.
• The findings contribute to advancing risk assessment in multiple myeloma.